We are proud to share that our portfolio company, KaloCyte, Inc., was featured in an article in Science Magazine on the development of their synthetic blood substitute. Kalocyte is spearheading the development of ErythroMer, an artificial red blood cell product, which addresses the urgent need for a reliable and easily accessible blood substitute, especially in trauma situations where traditional blood transfusions are not feasible. Karina Yazdanbakhsh, our vice president and director of research at New York Blood Center, agrees, calling the candidate blood substitute “promising” for use in trauma and other emergency settings. Congratulations to the KaloCyte team for their remarkable contributions to this life-saving technology! We are proud to be a part of their journey and we look forward to the successful future of this technology. KaloCyte, Inc., Allan Doctor, Elaine Haynes, Andrew Zaleski For more information, check out the full article below: https://lnkd.in/eJiswkmz
NYBC Ventures
Medical and Diagnostic Laboratories
We are the first venture fund dedicated to advancing innovation in blood-related and cellular medicines & technologies.
About us
Taking an agnostic approach to financing vehicles and structures and employing a model of patient capital, we have developed streamlined scientific and investment due diligence teams to evaluate investment and collaborative opportunities in benign hematology, infectious diseases, transfusion medicine, cell therapy, and regenerative medicine.
- Website
-
https://www.nybc.org/vtd-overview/
External link for NYBC Ventures
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 11-50 employees
- Type
- Nonprofit
- Founded
- 2022
Employees at NYBC Ventures
Updates
-
Thank you to Delaware BioScience Association for inviting our EVP, CBO and General Partner, Jay Mohr as a panelist at the 2024 Life Sciences Conference this past week. #DEDNA24
The second annual Delaware DNA conference hosted by the Delaware BioScience Association drew around 320 people seeking to gain perspective on the successes and challenges in the state’s pharmaceutical industry. #netde #InsiderOnly #bioscience #Delaware #pharma https://lnkd.in/gtTdftKn
Delaware DNA conference talks workforce ecosystem, innovation
https://delawarebusinesstimes.com
-
Thank you to the Convergence Forum for inviting our Managing Director, Meg Wood, to participate in an insightful panel discussion! It was a great session on "Understanding the Funding Strategy of Foundations." Thank you Motty Klots for the photo! #biotech #convergence2024
-
-
NYBC Ventures is thrilled to announce our investment in Vitestro, a pioneering company, transforming patient care with autonomous blood drawing technology. We are excited be part of their journey as they accelerate commercialization of their innovative blood drawing device. This technology marks significant progress in modernizing the blood draw experience for both patients and institutions. For more information on this announcement, please find the press release below. Jay Mohr, Christopher D. Hillyer, MD, Meg Wood, Toon Overbeeke, Sonder Capital
📢Breaking News from the Vitestro team! We're excited to share news of a $22 million (€20 million) funding round completion - a big milestone for the company and validation of its anticipated transformation of the healthcare sector. With this support, we can accelerate the commercialization of Vitestro's autonomous blood drawing device and expand our team to meet growing demand in Europe and the USA. Our technology is poised to transform what is one of the oldest and most common invasive procedures in all of medicine. Toon Overbeeke, CEO and co-founder: "I'm so proud of the Vitestro team, their dedication and hard work led to this strong endorsement and is setting us up for success in the coming years. We're also very grateful for the ongoing support from Sonder and existing private investors, and want to take a moment to welcome the new investors to the Vitestro team". The oversubscribed funding round was co-led by return investor Sonder Capital, with new investor NYBC Ventures, and participation from Invest-NL, European Investment Council Fund (European Innovation Council and SMEs Executive Agency (EISMEA)) and existing private investors. 🔗Read more (English): https://hubs.la/Q02vsJzf0 🔗Read more (Nederlands): https://hubs.la/Q02vsDTC0 In the photo: * Dr. Fred Moll (left), managing partner at Sonder Capital and co-founder of Intuitive Surgical, the company behind the da Vinci robot. * Toon Overbeeke (right), CEO and co-founder at Vitestro #Vitestro #BloodDrawDevice #MedTech #Funding
-
-
We are excited to share that our EVP, CBO and General Partner, Jay Mohr will be at Delaware BioScience Association 2024 Life Sciences Conference on May 9th. Don't miss this great panel on "Building a Thriving Life Sciences Ecosystem." Register now: https://bit.ly/48Vuo5g #DEDNA24 #DelawareBio #innovation
👏 Jay Mohr is one of the country’s top life science leaders, and we’re excited to announce a panelist at the Delaware DNA | 2024 Life Science Conference. Mohr is the EVP and Chief Business Officer at Comprehensive Cell Solutions (CCS), a cell and gene therapy development and manufacturing organization, a business unit of New York Blood Center. He has extensive strategic leadership in the biopharmaceutical industry, expertise in fundraising, investor relations, and product launches, and a track record of generating significant shareholder value. 🎤 Don’t miss this dynamic conversation on what goes into "Building a Thriving Life Science Ecosystem.” Register now for the event on May 9th: https://bit.ly/48Vuo5g #DEDNA24 #DelawareBio #innovation
-
Tune in to Richi Entrepreneurs Boston Talk, tomorrow April 17th at 10am EST to hear our Managing Director, Meg Wood, along with two other industry experts, share their insights on corporate strategic investing in life sciences. Reserve your spot now: https://lnkd.in/ebATvpPX
🚨 Don't Miss Tomorrow's Boston Talk! Are you ready to delve into the world of "Corporate Strategic Investors in Life Sciences"? Join us for an engaging session featuring industry experts Meg Wood from NYBC Ventures, Michael Baran from Pfizer Ventures, and Hugh (Ren) Roome from Boston Millennia Partners. With our distinguished host, Samuel Shafner, they'll unpack the intricacies of integrating corporate strategic investors into biotech startups, exploring key timing and considerations. 📅 Tomorrow, April 17th at 10 am EST, marks your opportunity to gather invaluable insights. Reserve your spot now and be part of the conversation 👇 https://lnkd.in/ebATvpPX
-
-
Exciting coverage from the Boston Globe Media of Rhode Island Blood Center's partnership with the All of Us Research Program. This partnership highlights New York Blood Center Enterprises commitment to being a great research partner and accelerating health research and medical breakthroughs. https://lnkd.in/e7RchJ7S
R.I. part of new effort to build one of the largest health databases - The Boston Globe
bostonglobe.com
-
🚀 Exciting news in cardiology and anticoagulants! A new class of anticoagulants targeting factor XI aims to prevent or reduce blood clots without increasing bleeding risks. NYBC Ventures is thrilled about our (not so) closely held portfolio company Aronora, Inc. involvement in this groundbreaking development. Factor XI inhibitors show promise in revolutionizing anticoagulation therapy, offering hope for improved patient outcomes. Stay tuned for updates as we follow the progress of this innovation! #Cardiology #Anticoagulants #Innovation #MedicalResearch https://lnkd.in/gurDEGkE
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
wsj.com
-
Join our Managing Director, Meg Wood at the 2024 Convergence Forum held on May 9th and 10th. To learn more about speaker and session information or to register for the event, follow the link here: https://lnkd.in/eqtP66Au #biotech #healthcare #leaders #convergence2024
-